Cingulate
CING50
$5.07arrow_drop_up2.63%$0.13
CING50
$5.07
arrow_drop_up2.63%Performance History
| Key Stats | |
|---|---|
| Open | $5.07 |
| Prev. Close | $5.17 |
| EPS | -326.40 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $11.11M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 4.85 | 5.23 |
| 52 Week Range | 1.80 | 187.20 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | -326.40 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Cingulate (CING)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Shane J. Schaffer Pharm.D., PharmD
- Headquarters
- Kansas City
- Employees
- 15
- Exchange
- NASDAQ
Keep an eye on Cingulate
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is the market capitalization of Cingulate (CING)?
Cingulate (CING) has a market capitalization of $11.27M. The average daily trading volume is 402.64K, indicating the stock's liquidity and investor engagement.
help
What is Cingulate's (CING) price per share?
The current price per share for Cingulate (CING) is $5.07. The stock has seen a price change of $0.13 recently, indicating a 2.63% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Cingulate (CING)?
For Cingulate (CING), the 52-week high is $187.2, which is 3.59K% from the current price. The 52-week low is $1.8, the current price is 181.67% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Cingulate (CING) a growth stock?
Cingulate (CING) has shown an average price growth of 0.41% over the past three years. It has received a score of 20 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cingulate as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Cingulate (CING) stock price performance year to date (YTD)?
As of the latest data, Cingulate (CING) has a year-to-date price change of -93.71%. Over the past month, the stock has experienced a price change of -60.39%. Over the last three months, the change has been -25.88%. Over the past six months, the figure is -61.94%.
help
Is Cingulate (CING) a profitable company?
Cingulate (CING) has a net income of -$23.53M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$22.76M. Furthermore, the EBITDA is -$18.05M.
News
CINGULATE INC.
SPECIAL MEETING OF STOCKHOLDERS
PRECISION TIMED RELEASE
ADHD
8/23/2024Cingulate Announces Adjournment of Special Meeting
CINGULATE INC.
CTX-1301
ADHD
EUROPEAN PATENT
8/15/2024Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
WD-40
EARNINGS
PRE-MARKET
STOCK MOVERS
7/11/2024Why WD-40 Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Benzinga
FINANCING AGREEMENTS
6/28/2024Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
CALENDAR OF EVENTS
6/25/2024Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
HEALTH
CLINICAL STUDY
6/25/2024Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance